Latest Disease-modifying antirheumatic drug Stories
Only three percent (n=181) of patients in the study cohort receiving anti-tumour necrosis factor agents (anti-TNFs) for treatment of their arthritis developed a first cancer within nine years and overall risk was not dependent on the type of arthritis.
LONDON and BRUSSELS, May 27, 2011 /PRNewswire/ -- UCB today announced data which showed that the addition of CimziaÂ® (certolizumab pegol) to current therapy was associated with a rapid and consistent clinical response in a diverse group of rheumatoid arthritis (RA) patients.
The American College of Rheumatology has developed new guidelines for starting and monitoring treatments for children with juvenile idiopathic arthritis.
A recent trial of rituximab in combination with a tumor necrosis factor (TNF) inhibitor and methotrexate (MTX) in patients with active rheumatoid arthritis (RA) found the safety profile to be consistent with other RA trials with TNF inhibitors.
Patients with rheumatoid arthritis, a crippling disease that eats away at the joints and causes severe pain and swelling, arenâ€™t receiving their much-needed, low-cost drugs that prevent deformity.
In a previous study, rheumatoid arthritis (RA) patients who failed to respond to methotrexate were shown to experience positive results with fostamatinib disodium (R788), an oral spleen tyrosine kinase (Syk) inhibitor that is thought to block immune cell signaling involved with bone and cartilage destruction.
Positive outcomes in rheumatoid arthritis (RA) are closely linked to early diagnosis and treatment with disease-modifying antirheumatic drugs (DMARDs).
BURLINGTON, Mass., Oct.
SOUTH SAN FRANCISCO, Calif., Sept. 29 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.
- A bereavement by loss of parents or children; the state of being orbate; orbation.